(ARE) Alexandria Real Estate - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0152711091
Stock: Laboratory, Campus, Office, Campus Amenities, Services
Total Rating 20
Risk 92
Buy Signal -0.77
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.30% |
| Yield on Cost 5y | 3.37% |
| Yield CAGR 5y | 1.10% |
| Payout Consistency | 95.6% |
| Payout Ratio | 689.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.0% |
| Relative Tail Risk | -5.33% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.11 |
| Alpha | -51.61 |
| Character TTM | |
|---|---|
| Beta | 0.766 |
| Beta Downside | 1.062 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.11% |
| CAGR/Max DD | -0.39 |
Description: ARE Alexandria Real Estate January 03, 2026
Alexandria Real Estate Equities (NYSE: ARE) is an S&P 500-listed REIT that specializes in purpose-built life-science campuses across major U.S. innovation hubs, including Greater Boston, the Bay Area, San Diego, Seattle, Maryland’s Bio-Park, the Research Triangle, and New York City. Founded in 1994, the company has positioned itself as the longest-tenured owner, operator, and developer of “Megacampus” ecosystems that foster collaborative research and commercial development.
Key performance indicators show strong fundamentals: occupancy across its portfolio remained above 96% in FY 2023, while funds-from-operations (FFO) grew roughly 10% year-over-year, driven by rising lease rates and a low vacancy environment. The life-science sector benefits from sustained macro-drivers such as a 5%-plus annual increase in U.S. biotech R&D spending and robust capital formation, which underpin demand for high-quality lab and office space.
For a deeper quantitative view, consider reviewing ValueRay’s detailed metrics on ARE’s valuation and cash-flow trends.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -1.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.14 > 1.0 |
| NWC/Revenue: -41.84% < 20% (prev -38.50%; Δ -3.33% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.41b > Net Income -1.43b |
| Net Debt (12.21b) to EBITDA (360.4m): 33.88 < 3 |
| Current Ratio: 0.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (170.4m) vs 12m ago -0.97% < -2% |
| Gross Margin: 68.94% > 18% (prev 0.70%; Δ 6824 % > 0.5%) |
| Asset Turnover: 8.30% > 50% (prev 8.13%; Δ 0.17% > 0%) |
| Interest Coverage Ratio: -4.37 > 6 (EBITDA TTM 360.4m / Interest Expense TTM 226.7m) |
Beneish M -2.32
| DSRI: 1.97 (Receivables 323.7m/168.5m, Revenue 2.97b/3.05b) |
| GMI: 1.02 (GM 68.94% / 70.19%) |
| AQI: 0.99 (AQ_t 0.94 / AQ_t-1 0.95) |
| SGI: 0.97 (Revenue 2.97b / 3.05b) |
| TATA: -0.08 (NI -1.43b - CFO 1.41b) / TA 34.08b) |
| Beneish M-Score: -2.32 (Cap -4..+1) = BBB |
What is the price of ARE shares?
As of February 08, 2026, the stock is trading at USD 55.90 with a total of 1,362,392 shares traded.
Over the past week, the price has changed by +2.31%, over one month by +6.72%, over three months by +6.69% and over the past year by -38.41%.
Over the past week, the price has changed by +2.31%, over one month by +6.72%, over three months by +6.69% and over the past year by -38.41%.
Is ARE a buy, sell or hold?
Alexandria Real Estate has received a consensus analysts rating of 3.54.
Therefor, it is recommend to hold ARE.
- StrongBuy: 3
- Buy: 1
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 60 | 7.3% |
| Analysts Target Price | 60 | 7.3% |
| ValueRay Target Price | 50 | -10.5% |
ARE Fundamental Data Overview January 31, 2026
P/E Forward = 16.6945
P/S = 3.1338
P/B = 0.6055
P/EG = 844.2
Revenue TTM = 2.97b USD
EBIT TTM = -990.0m USD
EBITDA TTM = 360.4m USD
Long Term Debt = 12.05b USD (from longTermDebt, last quarter)
Short Term Debt = 353.2m USD (from shortTermDebt, last quarter)
Debt = 12.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.21b USD (from netDebt column, last quarter)
Enterprise Value = 21.67b USD (9.45b + Debt 12.76b - CCE 549.1m)
Interest Coverage Ratio = -4.37 (Ebit TTM -990.0m / Interest Expense TTM 226.7m)
EV/FCF = 15.32x (Enterprise Value 21.67b / FCF TTM 1.41b)
FCF Yield = 6.53% (FCF TTM 1.41b / Enterprise Value 21.67b)
FCF Margin = 47.60% (FCF TTM 1.41b / Revenue TTM 2.97b)
Net Margin = -48.15% (Net Income TTM -1.43b / Revenue TTM 2.97b)
Gross Margin = 68.94% ((Revenue TTM 2.97b - Cost of Revenue TTM 922.6m) / Revenue TTM)
Gross Margin QoQ = 69.18% (prev 67.49%)
Tobins Q-Ratio = 0.64 (Enterprise Value 21.67b / Total Assets 34.08b)
Interest Expense / Debt = 0.51% (Interest Expense 65.7m / Debt 12.76b)
Taxrate = 21.0% (US default 21%)
NOPAT = -782.1m (EBIT -990.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.43 (Total Current Assets 939.8m / Total Current Liabilities 2.18b)
Debt / Equity = 0.82 (Debt 12.76b / totalStockholderEquity, last quarter 15.47b)
Debt / EBITDA = 33.88 (Net Debt 12.21b / EBITDA 360.4m)
Debt / FCF = 8.64 (Net Debt 12.21b / FCF TTM 1.41b)
Total Stockholder Equity = 16.69b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.00% (Net Income -1.43b / Total Assets 34.08b)
RoE = -8.57% (Net Income TTM -1.43b / Total Stockholder Equity 16.69b)
RoCE = -3.45% (EBIT -990.0m / Capital Employed (Equity 16.69b + L.T.Debt 12.05b))
RoIC = -2.63% (negative operating profit) (NOPAT -782.1m / Invested Capital 29.78b)
WACC = 3.95% (E(9.45b)/V(22.22b) * Re(8.74%) + D(12.76b)/V(22.22b) * Rd(0.51%) * (1-Tc(0.21)))
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.21%
[DCF Debug] Terminal Value 83.09% ; FCFF base≈1.45b ; Y1≈1.10b ; Y5≈675.7m
Fair Price DCF = 50.38 (EV 20.94b - Net Debt 12.21b = Equity 8.73b / Shares 173.3m; r=5.90% [WACC]; 5y FCF grow -28.40% → 2.90% )
EPS Correlation: -53.40 | EPS CAGR: -69.81% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.31 | Revenue CAGR: 5.71% | SUE: -2.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=-0.070 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=0.09 | Chg30d=+0.107 | Revisions Net=+0 | Growth EPS=+101.1% | Growth Revenue=-10.0%
EPS next Year (2027-12-31): EPS=-0.37 | Chg30d=-0.148 | Revisions Net=+0 | Growth EPS=-511.1% | Growth Revenue=-0.4%
P/S = 3.1338
P/B = 0.6055
P/EG = 844.2
Revenue TTM = 2.97b USD
EBIT TTM = -990.0m USD
EBITDA TTM = 360.4m USD
Long Term Debt = 12.05b USD (from longTermDebt, last quarter)
Short Term Debt = 353.2m USD (from shortTermDebt, last quarter)
Debt = 12.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.21b USD (from netDebt column, last quarter)
Enterprise Value = 21.67b USD (9.45b + Debt 12.76b - CCE 549.1m)
Interest Coverage Ratio = -4.37 (Ebit TTM -990.0m / Interest Expense TTM 226.7m)
EV/FCF = 15.32x (Enterprise Value 21.67b / FCF TTM 1.41b)
FCF Yield = 6.53% (FCF TTM 1.41b / Enterprise Value 21.67b)
FCF Margin = 47.60% (FCF TTM 1.41b / Revenue TTM 2.97b)
Net Margin = -48.15% (Net Income TTM -1.43b / Revenue TTM 2.97b)
Gross Margin = 68.94% ((Revenue TTM 2.97b - Cost of Revenue TTM 922.6m) / Revenue TTM)
Gross Margin QoQ = 69.18% (prev 67.49%)
Tobins Q-Ratio = 0.64 (Enterprise Value 21.67b / Total Assets 34.08b)
Interest Expense / Debt = 0.51% (Interest Expense 65.7m / Debt 12.76b)
Taxrate = 21.0% (US default 21%)
NOPAT = -782.1m (EBIT -990.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.43 (Total Current Assets 939.8m / Total Current Liabilities 2.18b)
Debt / Equity = 0.82 (Debt 12.76b / totalStockholderEquity, last quarter 15.47b)
Debt / EBITDA = 33.88 (Net Debt 12.21b / EBITDA 360.4m)
Debt / FCF = 8.64 (Net Debt 12.21b / FCF TTM 1.41b)
Total Stockholder Equity = 16.69b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.00% (Net Income -1.43b / Total Assets 34.08b)
RoE = -8.57% (Net Income TTM -1.43b / Total Stockholder Equity 16.69b)
RoCE = -3.45% (EBIT -990.0m / Capital Employed (Equity 16.69b + L.T.Debt 12.05b))
RoIC = -2.63% (negative operating profit) (NOPAT -782.1m / Invested Capital 29.78b)
WACC = 3.95% (E(9.45b)/V(22.22b) * Re(8.74%) + D(12.76b)/V(22.22b) * Rd(0.51%) * (1-Tc(0.21)))
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.21%
[DCF Debug] Terminal Value 83.09% ; FCFF base≈1.45b ; Y1≈1.10b ; Y5≈675.7m
Fair Price DCF = 50.38 (EV 20.94b - Net Debt 12.21b = Equity 8.73b / Shares 173.3m; r=5.90% [WACC]; 5y FCF grow -28.40% → 2.90% )
EPS Correlation: -53.40 | EPS CAGR: -69.81% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.31 | Revenue CAGR: 5.71% | SUE: -2.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=-0.070 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=0.09 | Chg30d=+0.107 | Revisions Net=+0 | Growth EPS=+101.1% | Growth Revenue=-10.0%
EPS next Year (2027-12-31): EPS=-0.37 | Chg30d=-0.148 | Revisions Net=+0 | Growth EPS=-511.1% | Growth Revenue=-0.4%